A common metabotropic glutamate receptor 5 (mGlu 5 ) allosteric site is known to accommodate diverse chemotypes. However, the structural relationship between compounds from different scaffolds and mGlu 5 is not well understood. In an effort to better understand the molecular determinants that govern allosteric modulator interactions with mGlu 5 we employed a combination of site-directed mutagenesis and computational modeling. With few exceptions, six residues (P654, Y658, T780, W784, S808 and A809) were identified as key affinity determinants across all seven allosteric modulator scaffolds. To improve our interpretation of how diverse allosteric modulators occupy the common allosteric site, we sampled the wealth of mGlu 5 structure-activity relationship (SAR) data available by docking 60 ligands (actives and inactives) representing seven chemical scaffolds into our mGlu 5 comparative model. To spatially and chemically compare binding modes of ligands from diverse scaffolds, the ChargeRMSD measure was developed. We found a common binding mode for the modulators that placed the long axes of the ligands parallel to the transmembrane helices 3 and 7. W784 in TM6 was not only identified as a key NAM cooperativity determinant across multiple scaffolds, but also caused a NAM to PAM switch for two different scaffolds. Moreover, a single point mutation in TM5, G747V, altered the architecture of the common allosteric site such that 4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (VU29) was noncompetitive with the common allosteric site. Our findings highlight the subtleties of allosteric modulator binding to mGlu 5 and demonstrate the utility in incorporating SAR information to strengthen the interpretation and analyses of docking and mutational data.
Introduction Glutamate, a primary excitatory neurotransmitter within the mammalian central nervous system, mediates its effects via interactions with ionotropic and metabotropic glutamate receptors (1) . The metabotropic glutamate receptors (mGlu) are a family of eight subtypes (mGlu 1 -mGlu 8 ) that belong to family C seven transmembrane-spanning G protein-coupled receptors (7TMR). Based on physiology and pathophysiology, metabotropic glutamate receptor subtype 5 (mGlu 5 ) is an attractive therapeutic target for a range of CNS-related disorders including: cognitive disorders, Fragile X Syndrome, anxiety, depression, Parkinson's disease and schizophrenia among others (2) .
However, selective targeting of mGlu 5 has been a challenge as the glutamate-binding (orthosteric) site is highly conserved across all mGlu subtypes. An alternative and highly successful approach is to target allosteric binding sites that are topographically distinct from the orthosteric site (3, 4) . The first of these so-called, allosteric modulators, to be discovered for mGlu 5 was MPEP (5, 6) . Allosteric modulators have the potential to enhance (positive allosteric modulators or PAMs) or inhibit (negative allosteric modulators or NAMs) the response to glutamate. A third category, silent (or neutral) allosteric modulators (SAMs) occupy allosteric sites but do not alter receptor activity. The magnitude and direction of allosteric modulation is referred to as cooperativity. In addition, multiple mGlu PAM scaffolds also exhibit intrinsic agonist activity in the absence of glutamate and such compounds are referred to as ago-PAMs (7) . At the ligand-receptor interaction level, what governs modulator affinity versus cooperativity and/or agonism remains to be fully appreciated.
In addition to increased subtype selectivity, allosteric modulators offer multiple theoretical advantages over competitive orthosteric ligands. Modulators that are quiescent in the absence of the endogenous agonist have the potential for spatial and temporal modulation of receptor function and therefore are able to 'fine-tune' receptor activity when the endogenous agonist is present. This is a particularly attractive feature for a CNS target as 'fine-tuning' neurotransmission may yield a better therapeutic outcome than sustained activation or blockade. Moreover, the cooperativity between the two sites is saturable, such that allosteric modulators reach a 'ceiling level' to their effect that could provide a larger therapeutic index.
Efforts to develop mGlu 5 allosteric modulators have been particularly successful. Numerous chemotypes have been disclosed that encompass the full range of modulator pharmacology, including weak and full NAMs, ago-PAMs, pure PAMs and SAMs. Despite this success, structure-activity relationships (SAR) for mGlu modulators are often difficult to interpret. Often, minimal changes to a molecule will translate to a complete loss of activity (8) . Furthermore, multiple mGlu chemotypes display "molecular switches'
where a PAM or SAM arises from a NAM scaffold and vice versa (9) . These molecular switches have been noted in numerous mGlu 5 modulator chemotypes (10) (11) (12) (13) (14) (15) and can also give rise to unanticipated changes in subtype selectivity (16) . This complexity in modulator SAR continues to be a challenge for drug discovery. It is important to note that the vast majority of discovery programs rely upon potency data alone, such that it remains to be determined whether the 'flat' or 'steep' SAR and 'molecular switches' may be attributed to changes in modulator affinity and/or cooperativity. Thus, there is a pressing need for a better understanding at both the ligand and receptor level as to what contributes to affinity versus cooperativity.
We sought to explore the structural determinants within mGlu 5 required for ligand binding to the common allosteric site, within and across different chemical scaffolds. We employed a suite of single point mutations that are either known or predicted to contribute to the common allosteric site (17) (18) (19) (20) (21) (22) (23) . Six key residues (P654, Y658, T780, W784, S808 and A809) were consistently implicated as affinity determinants for diverse PAMs and NAMs, validating that these seven chemotypes interact with a common binding pocket. However, a number of mutations showed differential effects on affinity and/or cooperativity between different scaffolds. To facilitate interpretation of mutagenic data and delineation of affinity versus cooperativity determinants, 9-10 analogs from each series, including active and inactive compounds, were docked into our comparative model of mGlu 5 . Building upon the previous observation that W784 was a crucial for MPEP cooperativity, we found that W784A caused a NAM to PAM switch for two different NAM scaffolds. Herein, we've taken advantage of the plethora of mGlu 5 SAR data to facilitate rationalization of binding pose selection for compounds docked to a mGlu 5 comparative model, strengthening hypotheses regarding the specific ligand-receptor contacts that dictate the binding and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 cooperativity of diverse allosteric modulators. The results highlight the subtleties of small molecule binding within the mGlu 5 7TM domain.
Results and Discussion

Probing determinants of allosteric modulation within the common allosteric site
A common allosteric site of mGlu 5 , originally characterized as a site for the mGlu 5 NAM MPEP (5, 22, 24) , recognizes multiple chemotypes that encompass the full array of allosteric ligand pharmacology including ago-PAMs, pure PAMs, NAMs and SAMs (3, 4, 10, 13) . Developing a deeper understanding of how allosteric ligands occupy the pocket and transmit their cooperativity will be important for interpreting the complexities inherent in allosteric modulator SAR. In addition, these insights will enrich our understanding of how class C GPCRs function and inform drug discovery efforts for this receptor class. To achieve this, we assessed representatives from seven allosteric modulator chemical scaffolds across a panel of single point mutations hypothesized to contribute to a common allosteric site in mGlu 5 (17) (18) (19) (20) (21) (22) . Building on our previous findings with MPEP, we assessed M-5MPEP, a related compound with lower affinity and cooperativity, in addition to three full NAMs: VU0285683, VU0366058 and VU0409106; two partial NAMs: VU0366248 and VU0366249; and two PAMs: VU29 and DPFE.
Mutations were screened for the effect of a single, sub-maximal modulator concentration (based on wildtype) to alter the glutamate concentration response curve for intracellular Ca 2+ mobilization ( Supplementary Fig. 1 ). Mutations that significantly altered modulation in the single concentration screen ( Supplementary Fig. 2) were assessed using the operational model of allosterism to determine modulator affinity and cooperativity estimates (25) . As expected for ligands interacting with a common pocket, many similarities were seen with respect to the impact of mutations on modulator affinity (Fig. 1 ).
<Figure 1>
Identification of NAM-receptor interactions that govern affinity
With few exceptions, P654, Y658, T780, W784, S808 and A809 were implicated as affinity determinants; in good agreement with previous studies (18) (19) (20) (21) (22) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 prototypical NAM, MPEP (17) . In our previous efforts investigating the binding modes of MPEP and acetylenic PAMs we found it difficult to computationally differentiate binding poses of these relatively linear ligands (17) . Therefore, we took advantage of the wealth of available SAR data for these different chemotypes to strengthen interpretations of putative binding poses with the aim to define the specific ligand-receptor interactions governing affinity and cooperativity. For mGlu 5 NAMs, with the exception of VU0285683 where very few analogs have been reported (12), we identified the best-in-class and minimally active pharmacophore for each scaffold ( Table 1 , Supplementary Fig. 3 ) and docked 9-12 analogs ( Fig.2 Supplementary Fig 4) . In comparison, traditional RMSD calculations only capture structural similarities between common atoms of ligands.
<Figure 2>
Direct interactions with S808 may mediate binding of NAMs with cyano substitutions on ring B
All five 4-aryl-5-cyanopyrimidine active ligands converged to two possible binding poses, one with the cyano group buried (Fig. 2a) , the other with the cyano group pointing towards extracellular space (Fig.   2b ). The 5-cyano is crucial for potency in this series (26) and if buried within the pocket, a hydrogen bond with T780 is predicted (Fig. 2a) . However, VU0366058 affinity was unaffected by T780A, favoring the cluster with 5-cyano pointing up (Fig. 2b) . A cyano group is also a key feature of the N-aryl benzamide NAMs (represented by VU0366248); substitution of ring B with 3-cyano yields the most potent ligands (27) . We postulate that the cyano group, or possibly the 5-fluoro, interacts with S808 (Fig. 2c) ; consistent with decreased N-aryl benzamide (VU0366248 and VU0366249) affinity at S808A while S808T increases affinity. Moreover, T780A had differential effects on the affinity of VU0366248 and VU0366249; these compounds only differ with respect to the position of fluoro substituent on ring A.
Interestingly, S808A reduced M-5MPEP affinity by 260 fold versus only 40 fold for MPEP. We previously hypothesized that S808 may be crucial for initial receptor recognition by MPEP via the pyridine ring. Indeed, the position of the nitrogen in the pyridine ring is crucial for NAM activity (28) .
Docking of acetylene NAMs with methoxy substituents (1C, 1F, 1G) on ring B (Fig. 2g) revealed the methoxy groups coordinated in close proximity to S808. Thus, the increased sensitivity of M-5MPEP to S808A may be related to the 2-methoxy group and/or the pyridine ring interacting with S808.
Furthermore, docking of the sub-nanomolar potency analog (1A) that contains a cyano substitution on ring B suggested a potential hydrogen bond with S808 (Fig. 2h) . Inactive compounds in both the 4-aryl-5-cyanopyrimidine and N-aryl benzamide series docked with the cyano group buried in the pocket ( Supplementary Fig. 5 ). VU0366058 and VU0285683 cooperativity was reduced at S808T and S808A, where these compounds could no longer abolish glutamate activity; however, MPEP and VU0409106 retained full blockade (Table 3) . Conversely, VU0366248 and VU0366249, both weak (or partial) NAMs at the wildtype receptor fully blocked glutamate activation of S808T, suggestive of increased negative cooperativity. Importantly, all four NAMs that show altered cooperativity contain a cyano group. These data lend additional support to diverse NAMs binding with ring B higher in the pocket and, where present, a cyano group directly interacting with S808.
Hydrophobic residue cluster in TM5/6 may limit substitution on ring B of NAMs
The most potent/highest affinity N-aryl benzamides, for e.g. 2A and 2B, have an additional phenyl substitution on ring B (29) . Examination of the putative binding pose reveals engagement of cluster of hydrophobic residues in TM5 and 6 (V739, L743, F787 and Y791); and potentially a polar interaction between the 4-fluoro of 2A and Y791. The result is a markedly different binding mode compared to reference compound VU0366248 (Fig. 2d) ; whereas analogs with a pyridine ring A (2D and 2G) align closer to the VU0366248 cluster. Furthermore, F787A and Y791A increased VU0366058 affinity by 13 and ~2.6 fold respectively (Y791A in supp table); this may be attributed to removal of steric constraints freeing up space in the pocket to accommodate the fluoro-phenyl substituent. These data lend even further support for the putative binding mode with 5-cyano pointing up (Fig. 2b) . Bulky substitutions of this Fig. 5 ) revealed that substantial re-orientation of binding pocket residues was required to accommodate the large substitutions of ring B (F787 for 1I and R647 for 1J). Collectively, these data are commensurate with the cluster of hydrophobic residues in TM5/6 having the potential to contribute to high affinity binding, but also limiting the size and polar nature of substitution on ring B of NAMs.
Surprisingly, the O-linked heteroaryl group of the aryl ether benzamide NAMs docked deeper into the binding pocket, rather than interacting with the TM5/6 hydrophobic cluster. This binding pose is favored due to multiple polar interactions predicted between the pyrimidine and backbone of TM7 residues and S657 and T780 side chains (Fig. 2e) . From the single concentration screen, S657A and S657C had no effect on modulation by VU0409106 ( Supplementary Fig. 5 ); however, T780A reduced affinity ~10 fold.
These data suggest that interactions with T780 and possibly TM7 are more crucial for high affinity binding of VU0409106 and analogs thereof. Further, for the most potent compounds in this series, chloro or fluoro substituents on benzamide ring A are located in the base of the pocket surrounded by W784, T780 and Y658, commensurate with the impact of mutations on VU0409106 affinity (Fig. 1 ). The minimally active compounds (5H and 5I) lack a substituent in this position, which may account for their drop in potency; whereas methoxy substitution (5G) requires movement of Y658 to occupy the same relative pocket (Fig. 2f ).
Amide containing NAMs are sensitive to N746A.
Interestingly, N746A significantly reduced N-aryl benzamide affinity (20 fold for VU0366248 and greater than 10 fold for VU0366249) and VU0409106 affinity (15 fold). Reduced affinity was also observed for to; such that N746 is important for the overall structure of the binding pocket rather than forming a direct ligand contact.
Determinants of N-aryl piperazine PAM binding
Previously we had examined the interactions of acetylenic PAMs within the common allosteric site of mGlu 5 (17) ; it was of interest whether or not PAMs from alternate scaffolds would share affinity and cooperativity determinants. On the whole, the N-aryl piperazines are low affinity, cooperativity driven
PAMs. Despite this limitation, three compounds from this series are efficacious in vivo (15, 31, 32) .
Consistent with interactions within the common allosteric site, P654S, Y658V, T780A, W784A, A809G
and A809V decreased affinity of DPFE (6-70 fold). In contrast to all other modulators tested to date, DPFE was unaffected by P654F (Fig 3a) . This may be attributable to increased flexibility of this compound allowing binding despite the introduction of a bulky hydrophobic group. Docking results suggest a conserved and relatively linear binding mode, with ring C oriented to the top of the pocket in the vicinity of the TM5/6 hydrophobic cluster and ring A buried; the carbonyl linker may participate in hydrogen bonds with TM7 residues (Fig. 3a) . The cyano groups at opposite ends of compounds 6B and 6C are in close proximity to T780 and S808 respectively. In support of this binding mode, we found that compound 6B (VU0364289) was sensitive to the S808A mutation ( Supplementary Fig. 7 ). This pose places the fluoro-phenyl of DPFE in close proximity to T780; Ala substitution of this residue had the most marked effect on DPFE affinity (70 fold; Fig. 3a ). Three additional point mutations had unique effects on DPFE: P742S decreased affinity (26 fold), L743V increased affinity (16 fold) and V788A
increased affinity (14 fold); affinity increases were confirmed with [ 3 H]methoxyPEPy binding assays ( Supplementary Fig. 8 ). Based on the proposed binding mode, these mutations may change the overall binding pocket architecture, in particular, in relation to the TM5/6 hydrophobic cluster and the capacity to 
Affinity determinants for diphenylpyrazole benzamide PAMs
In contrast to all other modulators, VU29 was unaffected by Y658V and compared with other PAMs had a moderate affinity reduction at T780A (17); possibly due to a lack of hydrogen bond partners in ring A (Fig. 3b ). This suggests that diphenylpyrazole benzamide PAM activity is driven via interactions higher in the pocket. All diphenylpyrazole benzamide series ligands docked with consistent positions of all three aromatic rings except for 4E ( Fig. 4d & 4e) . Notably, ring A of VU29 aligns well with the various NAMs;
however, neither ring B nor C overlap (Fig. 6 ). This deviates significantly from that proposed previously based on 3D superimposition of related ligands (29) . Further, substitution of the benzamide ring (B) is well tolerated (29, 34, 35) ; with polar interactions predicted between residues at the top of TM5/E2 loop ( Fig. 4d & 4e) . Moreover, benzamide phenyl replacement with a cyclopentane (4I) or addition of two methoxy groups (4J) significantly lowers PAM potency (36) . Furthermore, docking of inactive compounds showed deviation from actives, for e.g. phenyl ring C replacement with a pyridine that abolishes PAM activity (4H; Fig. 4f ). Indeed, pyridyl replacement or substitution of this phenyl is not tolerated (35) . G747V selectively reduced VU29 affinity (30-fold); therefore we assessed the ability of VU29 to inhibit [ 3 H]methoxyPEPy binding at G747V (Supplementary Fig. 8 ). VU29 behaved noncompetitively, unable to fully displace [ 3 H]methoxyPEPy binding; recent disclosure of potent dimeric MPEP analogs also suggested the common allosteric pocket could accommodate two ligands simultaneously (20, 37) . Collectively, these data support a global conformation change in the allosteric site architecture in G747V mutation particularly with respect to TM5/6 hydrophobic residues that may 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 interact with ring C (Fig. 4e) . This is an area of the binding pocket that the other modulators tested do not extend into, therefore accounting for the selective effect of this residue on VU29.
W784 is a NAM cooperativity determinant and can engenders a "molecular switch" to PAM
Similar to its effect on MPEP (17), W784A reduced cooperativity of the full NAMs VU0366058 and VU0409106 and abolished M-5MPEP cooperativity and/or affinity (Table 3) . Interestingly allosteric modulators VU0285683, VU0366248 and VU0366249 which all maintain a common 3-cyano-5-fluoro pendant phenyl ring, switched their pharmacology to PAMs (Fig. 5) states being engendered by allosteric modulators, such that this pharmacological mode switch relates to W784A favoring active states that are stabilized by certain modulators. In the case of NAMs VU0366248, VU0366249, and VU0285683 it's conceivable that these modulators have a limited mechanism of action on the molecular level, involving an alternative direct hydrogen bond with W784 with the common cyano moiety that is critical for stabilizing an inactive form of the receptor. In the absence of this interaction these modulators elicit moderate positive coooperativity with glutamate ( Fig. 6 , β: ~1.9-2.3). In contrast, VU0366058 and VU0409106, which do retain similar hydrogen bond accepting groups (e.g. cyano and thiazole, VU0366058 and VU0409106, respectively), may be envisioned as having additional interactions with the receptor that contribute to the negative cooperativity that is retained at the W784A mutant.
Consistent with this notion, VU0366058 and VU0409106 are structurally more complex with a greater number of rotatable bonds (3-4 vs. 2 RotB) and hydrogen bond acceptors (6 vs. 4); thus these compounds may be able to adopt multiple positions and/or conformations within the binding pocket to retain their 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 negative cooperativity. In addition, all three weak NAMs (M-5MPEP, VU0366248 and VU0366249) had reduced cooperativity at P654S and increased negative cooperativity at S657A. Together, these data suggest that 1) TM6, and W784 in particular, are crucial for adoption of active receptor states of family C 7TMRs and that 2) these differential effects on cooperativity provide evidence for stabilization of different inactive receptor conformations by individual chemotypes.
<Figure 5> <Figure 6>
PAM cooperativity determinants within the common allosteric site
Pharmacological mode switches at T780A, F787A or S808A have been observed for certain acetylene
PAMs and DFB (17, 21, 23) and their cooperativity with glutamate; neither VU29 nor DPFE showed mode switches at any of the mutations tested. However, both P742S and Y791A increased positive cooperativity, with increases also noted for VU29 at L743V and T780A ( Fig. 3c & d) . Interestingly, Y791A had very low responsiveness to glutamate prohibiting functional assessment of NAMs; however, this could be restored with PAMs (Fig. 3) . Collectively, the changes observed for modulator cooperativity highlight the importance of TM3, 5, 6 and 7 in the transmission of cooperativity by both negative and positive mGlu 5 allosteric modulators and infer a role for these TMs in the transition of the 7TM region from inactive to active states.
<Figure 7>
Docking PAMs into an inactive template
An important question in homology modeling GPCRs in complex with PAMs is whether a GPCR template in an 'active' state must be used. The critical question is if there is a systematic difference in the position of the upper transmembrane helices between 'active' and 'inactive' templates that might play a role when docking into such a distant sequence homologue? To answer this question we computed pairwise RMSDs between 'active' and 'inactive' structures using the structured-based alignment tool MAMMOTH (3.1±0.5 Å RMSD) (39) . This value is not significantly higher than the average pairwise RMSD between two inactive structures (2.9±0.6) or two active structures (2.8±0.6). We attribute this possibly surprising finding to several aspects: A) sequence similarity between GPCRs is so low that structural changes induced by a different sequence are larger than structural changes induced by activation, at least in the upper half of the trans-membrane spanning regions. B) One can also argue that many of the 'active' conformations might not be fully active as no G protein was bound. We conclude that there is no advantage in using an 'active' template when modeling such distant homologues as the structural changes between template and target will be much larger than changes induced by activation.
The Rosetta comparative modeling methods are unique in that the backbone template applied to the comparative model is only used to determine the initial placement in transmembrane helices. In the subsequent energy minimization steps, the backbone template is perturb on average 6-8 Å RMSD (40) . In information. This ensures that the final pose selected for each scaffold is within interaction distance to the residues implicated by mutagenesis (Fig. 6 ). Low potency, or inactive, compounds from available SAR were selected that retain some activity to avoid the potential confound of neutral allosteric ligands, i.e. allosteric ligands that occupy the binding pocket but do not modulate receptor activity. Thus these "inactive" ligands were assumed to be the result of low compatibility with the binding pocket. It is conceivable that inactive compounds may be the result of simply being unable to enter the binding pocket. Currently, for family C 7TMRs there is a lack of appreciation of how allosteric modulators access the transmembrane domains. Lipophilic compounds may enter the pocket via the lipid bilayer or from the top of the pocket opening to extracellular space. In the absence of a family C 7TMR crystal structure these models are not expected to provide high-resolution predictions. However, coupling of mutagenesisbased studies with comparative modeling of 7TMR's has provided powerful tools to study drug-receptor interactions for receptors where crystal structures are unavailable. We anticipate that employment of such a strategy would be operative at other receptors where crystal structures are not available. By applying an operational model of allosterism to quantify the impact of mutations on modulator pharmacology we have leant further power to these analyses, differentiating between effects on affinity versus cooperativity. We identified a single point mutation (W784A) that engendered a molecular switch in NAM pharmacology for two different scaffolds, providing additional insight from the protein perspective as to the propensity of mGlu 5 modulator SAR to display molecular switches. It is apparent that a deeper understanding of the specific ligand-receptor interactions has the potential to inform modulator design and potentially aid drug discovery efforts for this important CNS target.
Materials and Methods
Materials
Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS) and antibiotics were purchased from Invitrogen (Carlsbad, CA). VU0409106, VU0366058, VU0366248, VU0366249, M-5MPEP, VU29, DPFE and analogs thereof were all synthesized in-house using previously reported methodologies (13, 15, 26, 30, 31, 34, 42) . Synthesis of compound 6I is reported in the supplementary information. Unless otherwise stated, all other reagents were purchased from Sigma-Aldrich (St. Louis, MO) and were of an analytical grade. 
Cell culture
Mutations were introduced into the wild type rat mGlu 5 as described previously (17) . Polyclonal stable HEK293A-mGlu 5 mutant cell lines were maintained in complete DMEM supplemented with 10% FBS, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM Non-Essential Amino Acids, 1 mM sodium pyruvate, antibiotic-antimycotic and 500 µg/mL G418 at 37°C in a humidified incubator containing 5% CO 2 , 95% O 2 .
Intracellular Ca 2+ mobilization
Prior to assay, HEK293A-rat mGlu 5 cells were seeded at 50,000 cells/well in poly-D-lysine coated blackwalled, clear bottom 96 well plates in assay medium (DMEM with 10% dialyzed FBS, 20 mM HEPES, 1 mM sodium pyruvate). On the day of assay, the cell permeable Ca 2+ indicator dye Fluo-4 (Invitrogen, Carlsbad, CA) was used to assay receptor-mediated Ca 2+ mobilization as described previously (17, 25) using a Flexstation II (Molecular Devices, Sunnyvale, CA).
Docking allosteric modulators into the mGlu 5 comparative model
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